Clearmind Medicine
CMND
3 hedge funds and large institutions have $46.2K invested in Clearmind Medicine in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
285% more capital invested
Capital invested by funds: $12K → $46.2K (+$34.2K)
200% more funds holding
Funds holding: 1 → 3 (+2)
0.44% more ownership
Funds ownership: 0% → 0.44% (+0.44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$33.5K |
| 2 |
HF
HRT Financial
New York
|
+$24.6K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$1.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$9 |
CMND Hedge Fund Activity: Q1 2026 in Review
3 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Clearmind Medicine (CMND) for Q1 2026, worth a combined $46.2K — up 285% from $12K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CMND positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $33.5K. The largest seller was JP Morgan Chase, cutting an estimated $9.
- 3 institutional investors held Clearmind Medicine (CMND) as of Q1 2026, up from 1 in Q4 2025.
- Funds reported $46.2K of Clearmind Medicine stock for Q1 2026, up 285% quarter-over-quarter.
- 2 funds opened new Clearmind Medicine positions in Q1 2026 and 0 closed out, a net change of +2 holders.
- The largest Clearmind Medicine buyer in Q1 2026 was XTX Topco, an estimated $33.5K added.
- The largest Clearmind Medicine seller in Q1 2026 was JP Morgan Chase, an estimated $9 sold.
Based on aggregated 13F filings for Q1 2026.